Current Assets
Cash & Equivalents
AbbVie Cash & Equivalents increased by 79.6% to $9.39B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 81.5%, from $5.18B to $9.39B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -9.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026May 8, 2026
How to read this metric
An increase suggests strong liquidity and potential for investment, while a decrease may indicate heavy capital deployment or cash burn.
Detailed definition
This represents the most liquid assets held by the company, including currency, demand deposits, and highly liquid inves...
Peer comparison
Standard across all industries; peers typically maintain levels sufficient to cover short-term obligations and strategic flexibility.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.55B | $12.18B | $9.75B | $6.1B | $8.52B | $11.83B | $9.2B | $6.71B | $8.76B | $13.29B | $12.81B | $18.07B | $13.13B | $7.26B | $5.52B | $5.18B | $6.47B | $5.63B | $5.23B | $9.39B |
| QoQ Change | — | +42.5% | -20.0% | -37.4% | +39.7% | +38.9% | -22.2% | -27.1% | +30.5% | +51.7% | -3.6% | +41.0% | -27.3% | -44.7% | -23.9% | -6.3% | +25.0% | -13.0% | -7.1% | +79.6% |
| YoY Change | — | — | — | — | -0.3% | -2.9% | -5.6% | +10.1% | +2.8% | +12.3% | +39.3% | +169.2% | +49.9% | -45.4% | -56.9% | -71.4% | -50.7% | -22.4% | -5.3% | +81.5% |
Range$5.18B – $18.07B
CAGR+2.0%
Avg YoY Growth+6.5%
Median YoY Growth-1.6%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is AbbVie's cash & equivalents?
- AbbVie (ABBV) reported cash & equivalents of $9.39B in Q1 2026.
- How has AbbVie's cash & equivalents changed year-over-year?
- AbbVie's cash & equivalents increased by 81.5% year-over-year, from $5.18B to $9.39B.
- What is the long-term trend for AbbVie's cash & equivalents?
- Over 5 years (2020 to 2025), AbbVie's cash & equivalents has grown at a -9.2% compound annual growth rate (CAGR), from $8.45B to $5.23B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has on hand.